Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry

Mike Westby, Caroline Smith‐Burchnell, Julie Mori, +6

Journal of Virology

Phenotypic Susceptibility AssaysImmunologyCcr5 AntagonistPharmacotherapyViral Strains Resistant +14

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Mike Westby, Marilyn Lewis, Jeannette M. Whitcomb, +6

Journal of Virology

Ccr5 Antagonist MaravirocCcr5 TropicHuman RetrovirusPretreatment Cxcr4-using ReservoirImmunology +9

Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients

Luke C. Swenson, Tingting Mo, Winnie Dong, +10

The Journal of Infectious Diseases

Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing

John Archer, Michael Braverman, Bruce E. Taillon, +5

AIDS

Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies

Rachel A. McGovern, Alexander Thielen, Theresa Mo, +8

AIDS

Deep V3 Sequencing for HIV Type 1 Tropism in Treatment-Naive Patients: A Reanalysis of the MERIT Trial of Maraviroc

Luke C. Swenson, Theresa Mo, Winnie Dong, +12

Clinical Infectious Diseases

The Evolutionary Analysis of Emerging Low Frequency HIV-1 CXCR4 Using Variants through Time—An Ultra-Deep Approach

John Archer, Andrew Rambaut, Bruce E. Taillon, +3

PLoS Computational Biology

Population-Based Sequencing of the V3-loop Can Predict the Virological Response to Maraviroc in Treatment-Naive Patients of the MERIT Trial

Rachel A. McGovern, Alexander Thielen, Simon Portsmouth, +11

JAIDS Journal of Acquired Immune Deficiency Syndromes

ImmunodeficienciesPharmacotherapyR5 Hiv-1Antiviral DrugHiv/aids Counselling +18

Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Filibuvir in Hepatitis C Virus-Infected Patients

Philip J.F. Troke, Marilyn Lewis, Paul Simpson, +4

Antimicrobial Agents and Chemotherapy

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor

Xiaowei Jiang, Felix Feyertag, Conor J. Meehan, +6

Journal of Virology